Ms Hewson has over 35 years' experience in the finance sector. Ms Hewson has previously held long-term Non-Executive roles in a number of sectors, having held director appointments with Schroders Australia Limited, Stockland Group, BT Investment Management Limited, Westpac Banking Corporation, AGL Energy Limited, the Australian Gas Light Company, CSR Limited, AMP Limited, South Australian Water and the Economic Development Board of South Australia. Ms Hewson recently retired as a Non-executive Director of BHP Limited where she was Chairman of the BHP Remuneration Committee and a member of the Nomination and Governance Committee. She remains a Director of Infrastructure SA and a Member of the Federal Government Growth Centres Advisory Committee

Dr McNamee has executive experience in the biopharmaceutical industry, with a focus on strategy and creating long-term shareholder value. Dr McNamee has a global perspective and understanding of long-term capital projects in the pharmaceutical industry, with proven health, safety, environment and corporate responsibility. Dr McNamee has served as a Senior Advisor to private equity group Kohlberg Kravis Roberts. He has also pursued a number of private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government's Financial System Inquiry. In 2009, he was made an Officer of the Order of Australia for service to business and commerce. He is also a Chairman of GenesisCare Limited.He is also Chairman of the Innovation and Development Committee and member of of the Corporate Governance.

Dr Cuthbertson has over 35 years experience in medical research and biotech development with large biopharmaceutical companies and medical organisations. He also has non-executive director experience. Prior to CSL, he was a Senior Scientist at Genentech Inc, a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicine for people with life-threatening diseases. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne. He is also a Director of the Centre of Eye Research Australia and Director of the Grattan Institute. He is also a member of the Innovation and Development Committee.

Mr Brook has executive experience in industries, including mining, finance, manufacturing and chemicals. In particular, Mr Brook has insight and experience in relation to risk, capital discipline, change management, corporate culture and creating shareholder value. Mr Brook was Chief Financial Officer of WMC Resources Limited from 2002 to 2005. He also held key executive roles including Deputy Chief Finance Officer of ANZ Banking Group Limited, Group Chief Accountant of Pacific Dunlop Limited and General Manager, Group Accounting positions at CRA Limited and Pasminco Limited. He is also a Director of Newmont Goldcorp Corporation; Director of Incitec Pivot Limited; Director of Guide Dogs Victoria; Former Director and Chairman of Programmed Group; and Former Director of the Deep Exploration Technologies Co-operative Research Center Limited. He is also Chairman of the Risk Management Committee and member of the Corporate Governance.

Mr Perreault has more than 35 years of experience across both the global biotech and pharmaceutical industries. Prior to CSL, he spent more than 15 years in key senior roles at Wyeth-Ayerst Laboratories, now part of Pfizer.

Ms McDonald has executive and non-executive experience in a number of sectors including law, medical research, manufacturing and chemicals. Through these roles, Ms McDonald brings experience and insight on financial markets, risk and compliance and change management. Ms McDonald is a former lawyer with over 30 years experience in the legal sector. She was previously a partner of Ashurst, specialising in mergers and acquisitions and corporate governance. She held the role of National Head of Mergers and Acquisitions and was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia and a Member of the Australian Takeovers Panel for nine years. She is a Director of Nanosonics Limited (since October 2016); Director of Nufarm Limited (since March 2017); and Director of the Walter & Eliza Hall Institute of Medical Research (since October 2016). She is also a member of the Risk Management Committee, Member of the Human Resources.

Dr Clark has executive and non-executive experience across a range of sectors including scientific research, health, investment banking and financial services, education and mining. Dr Clark brings a strategic perspective and global experience, with a focus on risk and proven health, safety and environment and technology performance. Dr Clark was Chief Executive of the Commonwealth Scientific and Industrial Research Organisation (CSIRO) from 2009 until November 2014. Prior to joining CSIRO, she was a Director at NM Rothschild and Sons (Australia) and held senior positions at BHP, including Vice President Technology and Vice President Health, Safety and Environment. She is also a Director of Rio Tinto Limited and Rio Tinto Plc; Director of Care Australia Limited; member of the Australian advisory board of the Bank of America Merrill Lynch (since July 2010);member of Council of Monash University Council; and Head of the Australian Space Agency. She is also Chairman of the Human Resources; Member of the Corporate Governance committee,Innovation and Development Committee.

Mr Hussain has executive experience in the biopharmaceutical industry and biotechnology industry insight. Through his executive and non-executive roles, Mr Hussain has a global perspective and understanding of pharmaceutical manufacturing, product development, risk, health, safety, environment and corporate responsibility. Mr Hussain was the Global President, Pharmaceutical at GlaxoSmithKline (GSK) serving from 2008 to late 2017, where he managed a global pharmaceutical and vaccine business across 150 markets including the US, Europe, Japan and emerging markets. Before GSK he held senior roles with global responsibilities at Eli Lilly. He is also Director of Immunocore Limited (since May 2017); Director of Cochlear Limited (since December 2018); Senior Advisor on the Advisory Board of CellResearch Corporation (since August 2017); Senior Advisor at C-Bridge Capital (since October 2017); and Former Director of ViiV Healthcare Limited (from October 2009 to July 2017). He is a member of the Innovation and Development Committee, Member of the Human Resources Committee.

-

-